Roflumilast Versus Methotrexate in Psoriasis

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which is approved in its oral form for chronic obstructive pulmonary disease, and in its topical form in the treatment of plaque psoriasis. Methotrexate is one of the conventional systemic treatments of psoriasis, so the aim of this study is to compare the efficacy and safety of roflumilast and methotrexate in the treatment of psoriasis

Inclusion Criteria:Patients with psoriasis vulgarisPsoriatic patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our studyPsoriatic patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our studyExclusion Criteria:Erythrodermic or pustular psoriasisPregnant and lactating femalesPatients with autoimmune diseases e.g. systemic lupus erythematosusPatients with solid or hematological malignancies e.g., breast cancer, leukemia, etc.